C5041018 - A Phase 2 Open-Label, Single Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis - C5041018
Latest Information Update: 16 Mar 2026
At a glance
- Drugs Etrasimod (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms C5041018
- Sponsors Pfizer
Most Recent Events
- 16 Mar 2026 New trial record